Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 20/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30307065 | 0.89 | TACR1 (0.72) | TACR1 | |
| SCHEMBL2997671 | 0.89 | TACR1 (0.72) | TACR1 | |
| SCHEMBL23629620 | 0.89 | TACR1 (0.72) | TACR1 | |
| Water SCHEMBL7834521 | 0.88 | TACR1 (0.71) | TACR1 | |
| Hydrochloric Acid SCHEMBL7823238 | 0.88 | TACR1 (0.71) | TACR1 | |
| Hydrochloric Acid SCHEMBL7833330 | 0.88 | TACR1 (0.70) | TACR1 | |
| Oxalic Acid SCHEMBL8748967 | 0.87 | TACR1 (0.69) | TACR1 | |
| SCHEMBL7743767 | 0.86 | TACR1 (0.68) | TACR1 | |
| Lanepitant SCHEMBL14421491 | 0.85 | TACR1 (1.00) | TACR1 | |
| Lanepitant SCHEMBL6904907 | 0.85 | TACR1 (1.00) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0699665-B1 | Imidazoline derivatives, their preparation and their use as tachykinin receptor antagonists | LILLY CO ELI (US) | 2003-03-05 | — | — | EP | disclosed |
| US-6175013-B1 | 1-(2-METHOXYBENZYL)-2-((4-PHENYL-1-PIPERAZINYL)METHYL)-4-(1H -INDOL-3-YLMETHYL)-2-IMIDAZOLINE, FOR EXAMPLE; ADMINSTERING TO TREAT ANXIETY, DEPRESSION, PSYCHOSIS, AND SCHIZOPHRENIA | ELI LILLY AND COMPANY | 2001-01-16 | — | — | US | disclosed |
| EP-0699665-A1 | Imidazoline derivatives, their preparation and their use as tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 1996-03-06 | — | — | EP | disclosed |